Monopar Therapeutics Inc (MNPR) AI Stock Analysis

• Market Cap: $397.15M
• Dividend Yield: N/A
• Average Volume (3M): 303.04K
• Price to Earnings (P/E): ―
• Beta (1Y): 2.44
• Revenue Growth: N/A
• EPS Growth: -73.48%
• Country: US
• Employees: 14
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.48
• Shares Outstanding: 6,682,584
• 10 Day Avg. Volume: 316,158
• 30 Day Avg. Volume: 303,037
• PEG Ratio: -0.12
• Price to Book (P/B): 4.57
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -39.31
• Enterprise Value/Market Cap: 0.68
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: -13.45
• 1Y Price Target: $113.45
• Price Target Upside: 69.61% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 11
• EPS Forecast (FY): -3.23
• Revenue Forecast (FY): $400.00K

• Rating: 53 Neutral
• Price Target: $76.00 ▲(13.62% Upside)

The score is driven primarily by mixed financial performance—strong, low-debt balance sheet but ongoing pre-revenue losses and increasing cash burn. Technicals add downside pressure due to a clear downtrend, while the recent positive Phase 2 update provides an offsetting catalyst; valuation support is limited because earnings are negative and no dividend yield is provided.

Positive Factors

Low leverage / strong balance sheet

Extremely low debt and a much larger equity base materially reduce refinancing and solvency risk over the coming months. This stronger capital base gives management flexibility to fund clinical programs, negotiate partnerships, and withstand trial timelines without immediate debt pressure.

Positive Phase 2 clinical signal

Robust Phase 2 ALXN1840 data that shows rapid, sustained copper-balance improvement is a durable de-risking event for the lead program. Clinically meaningful efficacy can accelerate regulatory discussions, attract partners or licensing deals, and materially increase the asset's strategic value.

Focused, capital-efficient clinical model

A pure-play clinical development model concentrates resources on trial execution and asset advancement rather than commercial infrastructure. With a small workforce and targeted pipeline, the company can allocate capital to priority studies and remain attractive for collaborations that provide non-dilutive funding or milestone support.

Negative Factors

Pre-revenue business profile

Absence of product revenue means the company has no recurring cash generation and its long-term viability depends on successful clinical outcomes or third-party funding. This structural revenue gap increases execution risk and makes capital markets access critical to sustain operations.

Rising cash burn / negative operating cash flow

Growing negative operating cash flow indicates accelerating cash consumption to fund R&D. Persistent burn increases dependency on external financing, risking dilution or unfavorable deal terms; it also constrains the firm's ability to pursue multiple programs or extend runway without capital raises.

Widening net losses and negative returns

Expanding net losses and consistently negative ROE erode shareholders' equity over time unless offset by successful asset commercialization or partnerships. Structural unprofitability reduces retained capital for growth and increases the pressure to secure dilutive or dilutive-equivalent financing.

Monopar Therapeutics Inc Business Overview & Revenue Model

Company Description

Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer. The company also engages in developing Camsirubicin, an analog of doxorubicin, which is in Phase 1b clinical trial for the treatment of advanced soft tissue sarcoma; MNPR-101, a urokinase plasminogen activator receptor targeted antibody for the treatment of various cancers; MNPR-101 RIT, a radioimmunotherapeutic based on MNPR-101 for the potential treatment of cancer and severe COVID-19; and MNPR-202, an analog of camsirubicin to potentially treat doxorubicin-and camsirubicin-resistant cancers. Monopar Therapeutics Inc. has collaborations with the Grupo Español de Investigación en Sarcomas for the development of camsirubicin in patients with advanced soft tissue sarcoma; NorthStar Medical Radioisotopes, LLC to develop radio-immuno-therapeutics targeting severe COVID-19; and the Cancer Science Institute of Singapore to evaluate the activity of MNPR-202 and related analogs in various types of cancer. The company was incorporated in 2014 and is headquartered in Wilmette, Illinois.

How the Company Makes Money

Monopar Therapeutics Inc. primarily makes money through the development and potential commercialization of its drug candidates. The company is in a clinical-stage, meaning its revenue model is largely oriented towards the successful advancement of its drug pipeline through clinical trials. Revenue streams may include potential milestone payments and royalties from partnerships or licensing agreements with larger pharmaceutical companies. Additionally, Monopar may receive government grants or funding from non-profit organizations to support its research and development efforts. The company's financial success is heavily reliant on the clinical and regulatory success of its product candidates, as well as its ability to establish strategic collaborations.

Monopar Therapeutics Inc Financial Statement Overview

Summary

Financials are mixed: the balance sheet is a strength with very low debt and a much larger asset base, but the company remains pre-revenue with widening net losses and consistently negative operating/free cash flow, increasing reliance on external funding.

Income Statement

MNPR is still a pre-revenue biotech (revenue is $0 across annual periods and TTM (Trailing-Twelve-Months)), so profitability is driven entirely by R&D and operating spend. Losses have widened meaningfully in TTM (Trailing-Twelve-Months) (net loss of ~$19.4M vs. ~$15.6M in 2024), indicating higher burn and/or stepped-up development activity. A positive is that losses are not volatile quarter-to-quarter in the data provided (consistently negative), but the lack of revenue and expanding losses keep the score low.

Balance Sheet

The balance sheet is a clear strength: leverage is extremely low (TTM total debt ~$0.1M against ~$141.6M of equity), which reduces financial risk and refinancing pressure. Total assets have increased sharply versus 2024 (assets ~$144.2M vs. ~$60.3M), suggesting a strengthened capital base. The key weakness is that returns on equity remain negative due to ongoing losses (negative ROE in all periods), meaning the strong equity position is being consumed by operating deficits over time.

Cash Flow

Cash generation is weak, with negative operating cash flow and negative free cash flow in every period shown. Cash burn increased in TTM (Trailing-Twelve-Months) (operating cash flow about -$10.8M vs. about -$6.4M in 2024), which heightens funding dependence. A modest positive is that cash burn has not deteriorated every single year (some variability and a positive free cash flow growth figure in TTM), but overall the business is not self-funding and remains reliant on external capital.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	0.00	0.00	0.00	0.00	0.00	0.00
Gross Profit	0.00	0.00	0.00	0.00	0.00	0.00
EBITDA	-20.04M	-16.16M	-8.83M	-10.54M	-9.13M	0.00
Net Income	-19.44M	-15.59M	-8.40M	-10.52M	-9.10M	-6.30M
Balance Sheet
Total Assets	144.20M	60.29M	7.35M	13.23M	20.52M	16.87M
Cash, Cash Equivalents and Short-Term Investments	143.68M	60.21M	7.27M	13.12M	20.30M	16.74M
Total Debt	102.24K	0.00	0.00	8.41K	0.00	0.00
Total Liabilities	2.64M	5.25M	1.76M	3.14M	1.58M	1.18M
Stockholders Equity	141.56M	55.04M	5.59M	10.09M	18.94M	15.69M
Cash Flow
Free Cash Flow	-10.83M	-6.40M	-7.86M	-7.23M	-7.32M	-4.66M
Operating Cash Flow	-10.83M	-6.40M	-7.86M	-7.23M	-7.32M	-4.66M
Investing Cash Flow	-15.60M	-14.34M	4.93M	-4.92M	0.00	0.00
Financing Cash Flow	148.10M	59.29M	2.03M	32.87K	10.88M	8.18M

Monopar Therapeutics Inc Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 66.89
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For MNPR, the sentiment is Negative. The current price of 66.89 is below the 20-day moving average (MA) of 67.43, below the 50-day MA of 71.74, and above the 200-day MA of 57.16, indicating a neutral trend. The MACD of -1.71 indicates Positive momentum. The RSI at 37.47 is Neutral, neither overbought nor oversold. The STOCH value of 26.92 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for MNPR.

Monopar Therapeutics Inc Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
VNDA	60 Neutral	$449.13M	-5.31	-16.72%	―	11.12%	-406.76%
MNPR	53 Neutral	$397.15M	―	-26.54%	―	―	-73.48%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
VSTM	48 Neutral	$511.42M	―	-2888.70%	―	33.79%	-26.37%
SLN	47 Neutral	$203.11M	-2.57	―	―	―	―
MREO	45 Neutral	$65.23M	-1.56	-69.98%	―	―	―
CRDF	44 Neutral	$106.43M	-1.99	-102.71%	―	-27.29%	16.40%

Monopar Therapeutics Inc Corporate Events

Monopar Therapeutics Unveils Promising Phase 2 Study Results

On November 9, 2025, Monopar Therapeutics presented new data from the Phase 2 ALXN1840-WD-204 copper balance study at The Liver Meeting® 2025. The study showed that ALXN1840 (tiomolybdate choline) led to rapid and sustained improvement in daily copper balance in Wilson disease patients, primarily through increased fecal copper excretion, marking a significant advancement in treatment options for this condition.

The most recent analyst rating on (MNPR) stock is a Buy with a $115.00 price target. To see the full list of analyst forecasts on Monopar Therapeutics Inc stock, see the MNPR Stock Forecast page.